TAVR or Surgery for Intermediate-Risk Patients? (GARY Registry)

New findings from the GARY (German Aortic Valve Registry) registry show that intermediate-risk patients with severe aortic stenosis presented significantly higher mortality at 1 year when treated with transcatheter aortic valve replacement (TAVR) rather than with conventional surgery.

 

Results reflect everyday realities, which might include various bias tipping the scales towards one strategy or the other, and which could have contributed to the results.

 

The survival difference favoring surgery shown in the registry persisted even after propensity-score matching, but that does not rule out the presence of many other unadjusted confounding variables.

 

Almost 50,000 patients were enrolled in the GARY registry between January 2011 and December 2013, of whom 22.7% presented intermediate surgical risk (logistic EuroSCORE 10-20%).

 

Overall, 5997 patients who underwent TAVR or isolated valve surgery were included in the analysis.

 

Baseline differences between groups were striking, since patients who underwent TAVR showed higher surgical risk, presented greater age, worse heart failure, more prior myocardial infarction, more atrial fibrillation The most frequent reasons underlying the choice of TAVR over surgery were patient age and frailty.

 

Many of these factors might have affected the rate of all-cause mortality at a year: 8.9% for surgery vs. 16.6% for TAVR (p < 0.001).

 

The decision to choose one strategy over the other was made by a heart team in over 90% of patients, and it is clearly impossible to adjust for medical opinion.

 

Original title: Patients at Intermediate Surgical Risk Undergoing Isolated Interventional or Surgical Aortic Valve Replacement for Severe Symptomatic Aortic Valve Stenosis.

Presenter: Werner N.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...